Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Arena Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Arena Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Arena Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Arena Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Arena Pharmaceuticals, Inc.'s pipeline products Reason to Buy - Evaluate Arena Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Arena Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Arena Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Arena Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arena Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Arena Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Arena Pharmaceuticals, Inc. Snapshot 5 Arena Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Arena Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Arena Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Arena Pharmaceuticals, Inc. - Pipeline Products Glance 14 Arena Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Filing rejected/Withdrawn Products/Combination Treatment Modalities 15 Arena Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Arena Pharmaceuticals, Inc. - Drug Profiles 18 lorcaserin hydrochloride 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ralinepag 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 APD-334 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 APD-371 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 temanogrel hydrochloride 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Arena Pharmaceuticals, Inc. - Pipeline Analysis 27 Arena Pharmaceuticals, Inc. - Pipeline Products by Target 27 Arena Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 28 Arena Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 29 Arena Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 30 Arena Pharmaceuticals, Inc. - Recent Pipeline Updates 31 Arena Pharmaceuticals, Inc. - Dormant Projects 40 Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 APD-597 41 nelotanserin 41 Arena Pharmaceuticals, Inc. - Company Statement 42 Arena Pharmaceuticals, Inc. - Locations And Subsidiaries 46 Head Office 46 Other Locations & Subsidiaries 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Arena Pharmaceuticals, Inc., Key Information 5 Arena Pharmaceuticals, Inc., Key Facts 5 Arena Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7 Arena Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8 Arena Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9 Arena Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015 10 Arena Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11 Arena Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 12 Arena Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 13 Arena Pharmaceuticals, Inc. - Pre-Registration, 2015 14 Arena Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2015 15 Arena Pharmaceuticals, Inc. - Phase II, 2015 16 Arena Pharmaceuticals, Inc. - Phase I, 2015 17 Arena Pharmaceuticals, Inc. - Pipeline by Target, 2015 27 Arena Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 28 Arena Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 29 Arena Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 30 Arena Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 31 Arena Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 40 Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 41 Arena Pharmaceuticals, Inc., Subsidiaries 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.